Survey: Regulation hampers sustainability efforts

Validation and regulatory concerns top a list of obstacles that manufacturers face in adopting sustainability practices. Time constraints and a lack of in-house expertise are additional factors, according to a PharmaManufacturing.com survey. Article

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.